Bacher U et al. Prognostic relevance of FLT3-TKD mutations in AML: The combination matters — An analysis of 3082 patients. Blood 2008;111(5):2527-37. Abstract
Dohner K et al. Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood 2020;135(5):371-80. Abstract
Dohner H et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017;129(4):424-47. Abstract
Gale RE et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776–84. Abstract
Harada Y et al. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk Res 2018;66:20-7. Abstract
Knapper S et al. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 2017;129(9):1143-54. Abstract
Levis M. FLT3/ITD AML and the law of unintended consequences. Blood 2011;117(26):6987-90. Abstract
Perl AE et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med 2019;381:1728-40. Abstract
Perl AE et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: A multicentre, first-in-human, open-label, phase 1-2 study. Lancet Oncol 2017;18(8):1061-75. Abstract
Pratz KE et al. FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 2010;115(7):1425-32. Abstract
Ravandi F et al. Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia. Leukemia 2014;28(7):1543-5. Abstract
Rollig C et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial. Lancet Oncol 2015;16(16):1691-9. Abstract
Serve H et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: Results from a randomized, placebo-controlled trial. J Clin Oncol 2013;31(25):3110-8. Abstract
Stone RM et al. Midostaurin in FLT3-mutated acute myeloid leukemia. N Engl J Med 2017;377(19):1903. Abstract
Zarrinkar PP et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Blood 2009;114(14):2984-92. Abstract